Biotech and pharmaceutical R&D teams
You work in neuroscience and need biomarker or imaging statistics you can defend.
Drug Development & Trial Analytics
Biomarker analysis, trial-planning statistics and independent model checks for teams developing treatments for brain and age-related diseases.
Who this is for
Teams we help in this field.
Academic translational groups
You are preparing an early-phase study and need an endpoint and a sample size.
CROs and consultants
You need specialist imaging or brain-age statistics alongside your own team.
Audiences we welcome, not a list of clients.
Questions we help answer
What teams in this field ask us.
- Which imaging or digital biomarker could help select participants for our trial?
- How many participants do we need for an imaging endpoint?
- Is our disease-progression or prediction model good enough to rely on?
- How should exploratory biomarker analyses be pre-specified?
- What does the published evidence say about AI biomarkers for early Alzheimer's disease?
- How much does a brain measure change over a year in people like our participants?
What you receive
- An evidence memo: what the literature supports, and where it is thin.
- A simulation-based sample-size report: with the assumptions stated and varied.
- Analysis-plan sections: for exploratory biomarker endpoints, ready for your protocol.
- A model validation report: discrimination, calibration and external validity.
- Reproducible code: so your team can rerun every number.
Methods we use
The methods specialists ask about.
- Simulation-based power
- Mixed models for repeated measures
- Enrichment analysis
- Nested cross-validation
- Calibration
- External validation
- MRI morphometry
- Brain age
Evidence
Published work behind this area.
Advancements and challenges in using AI for biomarker detection in early Alzheimer's disease
Reviewed where AI biomarkers for early Alzheimer's disease stand, and their open problems.
Read the paper (external site)Neuroanatomical Signature of the Transition from Normal Cognition to MCI in Parkinson's Disease
Mapped brain changes as people with Parkinson's disease move from normal cognition to MCI.
Read the paper (external site)Bias-adjustment in neuroimaging-based brain age frameworks: A robust scheme
A bias-adjustment scheme for brain-age measures used as study outcomes.
Read the paper (external site)Boundaries
Our part is the data and biomarker side, not the chemistry. We do not do laboratory or compound-screening work, operate GCP-validated or 21 CFR Part 11 systems, act as statistician of record for a regulated trial, or prepare regulatory submissions. We support planning and exploratory, research-use analyses.
Packages that fit
Start at the right scale.
The same packages and prices on every page. Each starts with a written scope.
Research Diagnostic
Fixed priceCAD 495
- 60-minute video call
- Two-page risks and next-steps memo
- Optional 30-minute debrief
Paid in full at booking.
Memo within 5 business days of the call.
Ask about thisAnalysis Plan Sprint
Fixed priceCAD 1,250
- Analysis and validation plan
- Scoped sample-size or power calculation
- Methods text or reviewer response
50% to start; 50% on delivery.
Delivery date agreed in the written scope.
Ask about thisData-to-Results Sprint
FromCAD 3,000
- Agreed analysis and quality-control log
- Figures, tables and methods text
- R or Python code and recorded environment
50% to start; 50% on delivery.
Final price and delivery date agreed after scoping.
Ask about thisRelated
Go deeper.
Questions
About working in drug development & trial analytics.
Do you work on regulated (GCP) trials?
Only on planning and exploratory analyses outside the validated trial systems. The sponsor's statistician of record remains responsible for the regulated analysis.
Can you sign our NDA?
Yes, before any confidential document or data are shared.
Who owns the code and results?
You do, once the invoice is paid, unless the written scope says otherwise.
Can you work alongside our CRO?
Yes. We agree in writing who owns each analysis, so nothing is done twice.
Can you estimate how much a brain measure changes in a year?
Yes, from published data or your own pilot data, with the uncertainty shown. This number drives the sample size of an imaging endpoint.
How quickly can you start?
After a short call and a written scope. The Research Diagnostic is the fastest way to start: a 60-minute review and a written memo.
Discuss a drug development project.
Start with a short, non-confidential description. We reply with a suggested next step.